Clinical and pathologic characteristics of familial prostate cancer in Asian population

Myong Kim, Jung Kwon Kim, Changhee Ye, Hakmin Lee, Jong Jin Oh, Sangchul Lee, Seong Jin Jeong, Sang Eun Lee, Sung Kyu Hong, Seok Soo Byun

Research output: Contribution to journalArticle

Abstract

Background: We investigated prevalence of familial and hereditary prostate cancer (PCa) in Asian population, and compared clinical characteristics between familial and sporadic disease. Methods: Pedigrees of 1102 patients who were treated for PCa were prospectively acquired. Clinical and pathologic characteristics and biochemical recurrence (BCR)-free survival were compared between familial PCa and sporadic PCa in patients who underwent radical prostatectomy (RP; n = 751). Results: The prevalence of familial, first-degree familial, and hereditary PCa was found to be 8.4%, 6.7%, and 0.9%, respectively; similar result was obtained in patients who underwent RP (8.4%, 6.4%, and 0.9%). Patients with familial PCa were significantly younger than those with sporadic PCa (63.3 vs 65.6 years; P =.015). However, preoperative variables (prostate-specific antigen, clinical stage, biopsy Gleason score [GS], and percentage of positive biopsy cores) and postoperative variables (surgical GS, upgrading rate, pathologic stage, and percentage of tumor volume) did not correlate with family history (P range:.114–.982). Kaplan-Meier analysis of 5-year BCR-free survival revealed no significant difference between sporadic (82.7%), familial (89.4%; P =.594), and first-degree familial (87.1%; P =.774) PCa. Analysis of p53, Bcl-2, Ki67, and other immunohistochemistry biomarkers revealed that only increasing p53 expression and first-degree familial PCa approached significance (P =.059). Conclusion: The prevalence of familial PCa was somewhat lower in the Asian population than in other ethnic groups. Clinical and pathologic variables and selected histologic biomarker abnormalities were not significantly different in patients with and without a family history of PCa. BCR-free survival following RP was also unaffected by family history.

Original languageEnglish
JournalProstate
DOIs
StateAccepted/In press - 1 Jan 2019

Fingerprint

Prostatic Neoplasms
Population
Neoplasm Grading
Recurrence
Survival
Biomarkers
Biopsy
Familial Prostate cancer
Kaplan-Meier Estimate
Pedigree
Prostate-Specific Antigen
Prostatectomy
Tumor Burden
Ethnic Groups
Immunohistochemistry

Keywords

  • clinical characteristics
  • familial
  • hereditary
  • pathologic characteristics
  • prostate cancer

Cite this

@article{49263adc282f4492b332631d00d6aa39,
title = "Clinical and pathologic characteristics of familial prostate cancer in Asian population",
abstract = "Background: We investigated prevalence of familial and hereditary prostate cancer (PCa) in Asian population, and compared clinical characteristics between familial and sporadic disease. Methods: Pedigrees of 1102 patients who were treated for PCa were prospectively acquired. Clinical and pathologic characteristics and biochemical recurrence (BCR)-free survival were compared between familial PCa and sporadic PCa in patients who underwent radical prostatectomy (RP; n = 751). Results: The prevalence of familial, first-degree familial, and hereditary PCa was found to be 8.4{\%}, 6.7{\%}, and 0.9{\%}, respectively; similar result was obtained in patients who underwent RP (8.4{\%}, 6.4{\%}, and 0.9{\%}). Patients with familial PCa were significantly younger than those with sporadic PCa (63.3 vs 65.6 years; P =.015). However, preoperative variables (prostate-specific antigen, clinical stage, biopsy Gleason score [GS], and percentage of positive biopsy cores) and postoperative variables (surgical GS, upgrading rate, pathologic stage, and percentage of tumor volume) did not correlate with family history (P range:.114–.982). Kaplan-Meier analysis of 5-year BCR-free survival revealed no significant difference between sporadic (82.7{\%}), familial (89.4{\%}; P =.594), and first-degree familial (87.1{\%}; P =.774) PCa. Analysis of p53, Bcl-2, Ki67, and other immunohistochemistry biomarkers revealed that only increasing p53 expression and first-degree familial PCa approached significance (P =.059). Conclusion: The prevalence of familial PCa was somewhat lower in the Asian population than in other ethnic groups. Clinical and pathologic variables and selected histologic biomarker abnormalities were not significantly different in patients with and without a family history of PCa. BCR-free survival following RP was also unaffected by family history.",
keywords = "clinical characteristics, familial, hereditary, pathologic characteristics, prostate cancer",
author = "Myong Kim and Kim, {Jung Kwon} and Changhee Ye and Hakmin Lee and Oh, {Jong Jin} and Sangchul Lee and Jeong, {Seong Jin} and Lee, {Sang Eun} and Hong, {Sung Kyu} and Byun, {Seok Soo}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/pros.23917",
language = "English",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",

}

Clinical and pathologic characteristics of familial prostate cancer in Asian population. / Kim, Myong; Kim, Jung Kwon; Ye, Changhee; Lee, Hakmin; Oh, Jong Jin; Lee, Sangchul; Jeong, Seong Jin; Lee, Sang Eun; Hong, Sung Kyu; Byun, Seok Soo.

In: Prostate, 01.01.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Clinical and pathologic characteristics of familial prostate cancer in Asian population

AU - Kim, Myong

AU - Kim, Jung Kwon

AU - Ye, Changhee

AU - Lee, Hakmin

AU - Oh, Jong Jin

AU - Lee, Sangchul

AU - Jeong, Seong Jin

AU - Lee, Sang Eun

AU - Hong, Sung Kyu

AU - Byun, Seok Soo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: We investigated prevalence of familial and hereditary prostate cancer (PCa) in Asian population, and compared clinical characteristics between familial and sporadic disease. Methods: Pedigrees of 1102 patients who were treated for PCa were prospectively acquired. Clinical and pathologic characteristics and biochemical recurrence (BCR)-free survival were compared between familial PCa and sporadic PCa in patients who underwent radical prostatectomy (RP; n = 751). Results: The prevalence of familial, first-degree familial, and hereditary PCa was found to be 8.4%, 6.7%, and 0.9%, respectively; similar result was obtained in patients who underwent RP (8.4%, 6.4%, and 0.9%). Patients with familial PCa were significantly younger than those with sporadic PCa (63.3 vs 65.6 years; P =.015). However, preoperative variables (prostate-specific antigen, clinical stage, biopsy Gleason score [GS], and percentage of positive biopsy cores) and postoperative variables (surgical GS, upgrading rate, pathologic stage, and percentage of tumor volume) did not correlate with family history (P range:.114–.982). Kaplan-Meier analysis of 5-year BCR-free survival revealed no significant difference between sporadic (82.7%), familial (89.4%; P =.594), and first-degree familial (87.1%; P =.774) PCa. Analysis of p53, Bcl-2, Ki67, and other immunohistochemistry biomarkers revealed that only increasing p53 expression and first-degree familial PCa approached significance (P =.059). Conclusion: The prevalence of familial PCa was somewhat lower in the Asian population than in other ethnic groups. Clinical and pathologic variables and selected histologic biomarker abnormalities were not significantly different in patients with and without a family history of PCa. BCR-free survival following RP was also unaffected by family history.

AB - Background: We investigated prevalence of familial and hereditary prostate cancer (PCa) in Asian population, and compared clinical characteristics between familial and sporadic disease. Methods: Pedigrees of 1102 patients who were treated for PCa were prospectively acquired. Clinical and pathologic characteristics and biochemical recurrence (BCR)-free survival were compared between familial PCa and sporadic PCa in patients who underwent radical prostatectomy (RP; n = 751). Results: The prevalence of familial, first-degree familial, and hereditary PCa was found to be 8.4%, 6.7%, and 0.9%, respectively; similar result was obtained in patients who underwent RP (8.4%, 6.4%, and 0.9%). Patients with familial PCa were significantly younger than those with sporadic PCa (63.3 vs 65.6 years; P =.015). However, preoperative variables (prostate-specific antigen, clinical stage, biopsy Gleason score [GS], and percentage of positive biopsy cores) and postoperative variables (surgical GS, upgrading rate, pathologic stage, and percentage of tumor volume) did not correlate with family history (P range:.114–.982). Kaplan-Meier analysis of 5-year BCR-free survival revealed no significant difference between sporadic (82.7%), familial (89.4%; P =.594), and first-degree familial (87.1%; P =.774) PCa. Analysis of p53, Bcl-2, Ki67, and other immunohistochemistry biomarkers revealed that only increasing p53 expression and first-degree familial PCa approached significance (P =.059). Conclusion: The prevalence of familial PCa was somewhat lower in the Asian population than in other ethnic groups. Clinical and pathologic variables and selected histologic biomarker abnormalities were not significantly different in patients with and without a family history of PCa. BCR-free survival following RP was also unaffected by family history.

KW - clinical characteristics

KW - familial

KW - hereditary

KW - pathologic characteristics

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85074864009&partnerID=8YFLogxK

U2 - 10.1002/pros.23917

DO - 10.1002/pros.23917

M3 - Article

C2 - 31664733

AN - SCOPUS:85074864009

JO - Prostate

JF - Prostate

SN - 0270-4137

ER -